The effect and safety of the drug Acyclovir in patients of Pityriasis rosea (a widespread red and scaly lesion following infection or drug intake)

A STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF ACYCLOVIR IN PITYRIASIS ROSEA: AN INVESTIGATOR-BLIND RANDOMISED CLINICAL TRIAL - ESAPR

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/12/004240

Enrollment

Registered

2013-12-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Pityriasis rosea

Interventions

Intervention1: Acyclovir, Calamine lotion, Cetirizine: 400 mg acyclovir thrice daily for a duration of initial 7 days of the 4 week treatment. Patients will be receiving calamine lotion and Cetirizine

Eligibility

Inclusion criteria

Inclusion criteria: a. All patients presenting with pityriasis rosea. b. Patients giving informed written consent

Exclusion criteria

Exclusion criteria: a. Patients not willing to participate in the study b. Pregnant or breast feeding women c. Any history of sensitivity to acyclovir or erythromycin or cetirizine d. Renal or hepatic impairment e. Suspicion of having fungal infection, psoriasis, or eczema.

Design outcomes

Primary

Measure	Time frame
Assessment of symptoms (Symptom score) on a 0-10 scaleTimepoint: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks following randomoization	—

Secondary

Measure	Time frame
1. Spontaneously reported adverse events 2. Adverse events elicited by the clinicians Timepoint: 1 week, 2 weeks, 3 weeks, 4 weeks following randomoization	—

Countries

India

Contacts

Public ContactAmrita Sil

Medical College, Kolkata

drdasnilay@gmail.com9433394148

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026